Genmab
Bookmark
ShareCopied to clipboardGenmab is a company. It is a public company in Copenhagen, Denmark. It was founded in 1999 and its current CEO is Jan G.J. van de Winkel. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Copenhagen
- country: Denmark
- employees: 2,682 people
- revenues: 3.1B $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1999
- CEO: Jan G.J. van de Winkel
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Genmab:
Dataset of stocks from Genmab:
Genmab is one of the companies in Denmark, companies in Biotechnology, companies in Health Care, companies in Copenhagen and 3,456,808 companies in our database.
Talking Points
- Welcome to Genmab
- We are a leader in harnessing the power of human antibodies and our purpose is to improve the lives of people with cancer | Disclaimer https://t.co/E8NokG2tvL
- We are a leader in harnessing the power of human antibodies & our purpose is to improve the lives of people with cancer | Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in ...
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.